Hims stock landed in hot water this month after Novo Nordisk slammed the telehealth giant with a lawsuit over its knockoff ...

Hims & Hers Health (NYSE:HIMS) launched a compounded semaglutide weight loss pill, then quickly discontinued it after a patent infringement lawsuit from Novo Nordisk. The company is under increased ...

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $15.84, marking a -2.64% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.56%.

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock ...

Presented by the Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Legal pressures ...

Hims & Hers Health (NYSE:HIMS) has crashed 47.96% over the past month, falling from $31.32 on January 14 to $16.30 as of ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims ...

Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and HHS. The company now faces a lawsuit from Novo Nordisk for patent ...

The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, ...

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two ...

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon ...